200 related articles for article (PubMed ID: 11763426)
1. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma.
Ho DM; Hsu CY; Wong TT; Chiang H
J Neurooncol; 2001 Aug; 54(1):77-85. PubMed ID: 11763426
[TBL] [Abstract][Full Text] [Related]
2. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
[TBL] [Abstract][Full Text] [Related]
3. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
4. Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas.
Rushing EJ; Yashima K; Brown DF; White CL; Shay JW; Risser RC; Gazdar AF
J Neuropathol Exp Neurol; 1997 Oct; 56(10):1142-6. PubMed ID: 9329458
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.
Prayson RA
Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108
[TBL] [Abstract][Full Text] [Related]
6. Ependymomas: MIB-1 proliferation index and survival.
Ritter AM; Hess KR; McLendon RE; Langford LA
J Neurooncol; 1998 Oct; 40(1):51-7. PubMed ID: 9874186
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features of anaplastic myxopapillary ependymomas.
Lee JC; Sharifai N; Dahiya S; Kleinschmidt-DeMasters BK; Rosenblum MK; Reis GF; Samuel D; Siongco AM; Santi M; Storm PB; Ferris SP; Bollen AW; Pekmezci M; Solomon DA; Tihan T; Perry A
Brain Pathol; 2019 Jan; 29(1):75-84. PubMed ID: 30417460
[TBL] [Abstract][Full Text] [Related]
8. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
Ho DM; Hsu CY; Ting LT; Chiang H
Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in intracranial ependymomas in children.
Figarella-Branger D; Civatte M; Bouvier-Labit C; Gouvernet J; Gambarelli D; Gentet JC; Lena G; Choux M; Pellissier JF
J Neurosurg; 2000 Oct; 93(4):605-13. PubMed ID: 11014538
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases.
Prayson RA
Am J Clin Pathol; 1998 Nov; 110(5):629-34. PubMed ID: 9802348
[TBL] [Abstract][Full Text] [Related]
11. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
[TBL] [Abstract][Full Text] [Related]
12. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity.
Prayson RA
Mod Pathol; 1997 Apr; 10(4):304-10. PubMed ID: 9110291
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of histopathological ependymoma variants.
Neumann JE; Spohn M; Obrecht D; Mynarek M; Thomas C; Hasselblatt M; Dorostkar MM; Wefers AK; Frank S; Monoranu CM; Koch A; Witt H; Kool M; Pajtler KW; Rutkowski S; Glatzel M; Schüller U
Acta Neuropathol; 2020 Feb; 139(2):305-318. PubMed ID: 31679042
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma.
Wolfsberger S; Fischer I; Höftberger R; Birner P; Slavc I; Dieckmann K; Czech T; Budka H; Hainfellner J
Am J Surg Pathol; 2004 Jul; 28(7):914-20. PubMed ID: 15223962
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
[TBL] [Abstract][Full Text] [Related]
16. Prognostic marker analysis in pediatric intracranial ependymomas.
McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
[TBL] [Abstract][Full Text] [Related]
17. Cellular proliferation in pilocytic and diffuse astrocytomas.
Giannini C; Scheithauer BW; Burger PC; Christensen MR; Wollan PC; Sebo TJ; Forsyth PA; Hayostek CJ
J Neuropathol Exp Neurol; 1999 Jan; 58(1):46-53. PubMed ID: 10068313
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
Xi S; Sai K; Hu W; Wang F; Chen Y; Wang J; Zeng J; Chen Z
BMC Cancer; 2019 Jul; 19(1):717. PubMed ID: 31324163
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.
Witt H; Gramatzki D; Hentschel B; Pajtler KW; Felsberg J; Schackert G; Löffler M; Capper D; Sahm F; Sill M; von Deimling A; Kool M; Herrlinger U; Westphal M; Pietsch T; Reifenberger G; Pfister SM; Tonn JC; Weller M;
Neuro Oncol; 2018 Nov; 20(12):1616-1624. PubMed ID: 30053291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
